McKesson to Administer Cephalon Programs for Cancer Pain

Cephalon, a Woodlands, Texas, medical device company, has chosen McKesson Specialty Health to administer its FDA-approved FENTORA and ACIQ Risk Evaluation and Mitigation Strategy Programs for management breakthrough pain in cancer patients, according to a McKesson news release.

Advertisement

McKesson Specialty Health will now administer Cephalon REMS programs and McKesson’s sister organization RelayHealth will allow patients to have their prescriptions filled at any local retail pharmacy enrolled in the ACTIQ and FENTORA REMS programs.

Related Articles on McKesson:

CMS Chooses McKesson’s InterQual Criteria for Medicare Inpatient Services Audit Program

McKesson Partners With Lakewood health System in Minnesota

Fraud, Waste and Abuse Tools Integrate to McKesson Total Payment

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Advertisement

Next Up in Uncategorized

Advertisement

Comments are closed.